CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,954,082 | +624.7% | 401,953 | +339.1% | 0.03% | +700.0% |
| Q2 2023 | $1,649,461 | +219.0% | 91,535 | +184.3% | 0.00% | +300.0% |
| Q1 2023 | $517,132 | +14.8% | 32,200 | +30.8% | 0.00% | 0.0% |
| Q4 2022 | $450,400 | -1.4% | 24,612 | +5.8% | 0.00% | -50.0% |
| Q3 2022 | $457,000 | -47.6% | 23,256 | -50.2% | 0.00% | -33.3% |
| Q2 2022 | $872,000 | -67.1% | 46,745 | -61.3% | 0.00% | -62.5% |
| Q1 2022 | $2,651,000 | -32.0% | 120,777 | -12.0% | 0.01% | 0.0% |
| Q4 2021 | $3,900,000 | +26.7% | 137,292 | -6.2% | 0.01% | +14.3% |
| Q3 2021 | $3,079,000 | +40.5% | 146,292 | +25.8% | 0.01% | +40.0% |
| Q2 2021 | $2,192,000 | +147.7% | 116,310 | +100.7% | 0.01% | +150.0% |
| Q1 2021 | $885,000 | +16.3% | 57,944 | +7.5% | 0.00% | 0.0% |
| Q4 2020 | $761,000 | +79.5% | 53,911 | +99.1% | 0.00% | 0.0% |
| Q3 2020 | $424,000 | -55.0% | 27,077 | -49.7% | 0.00% | -60.0% |
| Q2 2020 | $943,000 | – | 53,812 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |